|Over a week ago|
Interpace Biosciences price target lowered to $11 from $12 at H.C. Wainwright » 06:1906/2606/26/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Yi Chen lowered the firm's price target on Interpace Biosciences to $11 from $12 and reiterates a Buy rating on the shares following the company's Q1 results.
Interpace Biosciences reports Q1 EPS ($2.32), consensus ($1.22) » 17:0306/2506/25/20
Reports Q1 revenue $9.2M,…
Reports Q1 revenue $9.2M, consensus $8.93M. CEO Jack Stover stated, "Q1 revenue was $9.2M and near the top end of our previously announced revenue range. During Q1 we continued to grow our Clinical and Pharma services businesses, however, our Clinical services business was impacted by the pandemic beginning in the second half of March. (...) While we were generally pleased with first quarter progress, we did experience the business impact from the coronavirus pandemic and while recovering, we do anticipate the impact will continue through the remainder of 2020 and perhaps beyond. Our focus for the rest of the year will be continuing to respond to changing conditions while positioning ourselves for growth and expansion, improving business processes and integrating our service offerings."
|Over a month ago|
Interpace Biosciences subsidiary announces contract with Avalon Healthcare » 06:5604/2704/27/20
Interpace Biosciences announced that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions, a specialty benefit management company. The new contract, whose terms were not disclosed, includes two of the Southeastern U.S.'s largest Blue Cross Blue Shield plans where members can now take advantage of the benefits of ThyGeNEXT and ThyraMIR thyroid testing while reducing their out of pocket expenses due to Interpace's status as an in-network provider. Interpace has successfully achieved positive medical coverage for its services through Medicare as well as other leading national and regional health plans and is now focused on establishing more contracts to optimize the adjudication process.
Interpace Biosciences price target lowered to $9.25 from $21 at Alliance Global » 20:1004/2304/23/20
Alliance Global Partners…
Alliance Global Partners analyst Ben Haynor lowered the firm's price target on Interpace Biosciences to $9.25 from reverse-split adjusted $21 but keeps a Buy rating on the shares. The analyst cites the company's below-consensus Q4 revenue as its billings collectors have been unable to collect at historical rates. Haynor adds that despite the sales shortfall, he was encouraged by the diagnostics volume growth, which remained high at ~25% for the year.
Interpace Biosciences price target lowered to $12 from $15 at H.C. Wainwright » 07:1404/2304/23/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Yi Chen lowered the firm's price target on Interpace Biosciences to $12 from $15 and reiterates a Buy rating on the shares following the company's sales miss in Q4.
Interpace Biosciences reports Q4 EPS ($2.89), consensus (74c) » 16:0904/2204/22/20
Reports Q4 revenue…
Reports Q4 revenue $4.07M, consensus $10.77M.
|Over a quarter ago|
Interpace Biosciences initiated with a Buy at Janney Montgomery Scott » 06:1604/1504/15/20
Janney Montgomery Scott…
Janney Montgomery Scott analyst Paul Knight initiated coverage of Interpace Biosciences with a Buy rating.
Interpace Diagnostics announces contract with BCBS of Massachusetts » 06:5603/1003/10/20
Interpace Diagnostics, a…
Interpace Diagnostics, a subsidiary of Interpace Biosciences, announced that it has entered into a contract with Blue Cross Blue Shield of Massachusetts with over 3M members in Massachusetts and across New England. The contract expands Interpace's ThyGeNEXT and ThyraMIR thyroid assays as both covered services and now in-network services for BCBS of Massachusetts' 3M members and their families. As a result of this Agreement, members of BCBS of Massachusetts can take advantage of the benefits of ThyGeNEXT and ThyraMIR testing due to Interpace's status as an in-network provider. While terms of this Agreement are not disclosed, Interpace now benefits from a claim adjudication perspective as an in-network lab. Interpace has also successfully achieved positive medical coverage for its services through Medicare as well as other leading National and Regional health plans and is now entering into contracts to confirm such agreements.
Interpace Biosciences announces extension of LabCorp agreement » 06:5602/2402/24/20
Interpace Biosciences (IDXG) announced that its agreement with LabCorp (LH) has been extended for an additional two years, through January 2022. Interpace and LabCorp initially entered in to their collaboration in 2016 through which LabCorp became the first national laboratory in the U.S. to offer electronic ordering and result reporting for Interpace's proprietary ThyGeNEXT and ThyraMIR tests for thyroid cancer. Terms of the agreement extension were not disclosed.
Interpace Biosciences CFO James Early to retire, of Fred Knechtel to succeed » 06:5701/3001/30/20
Early has been working at…
Early has been working at Interpace since 2016. Previously, Knechtel held numerous CFO roles with companies that range in size from $100M-$5B in revenue.